Pricing Log in Create free account
Friday 6 November 2026 Export IONS’s income statement to Excel — free account

Ionis Pharmaceuticals, Inc.

IONS Healthcare Biotechnology

Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.

Revenue
−40.7%
EPS
−188.5%
Free cash flow
+299.3%
Total debt
+116.0%

Quarter to June 2026, against a year earlier

39.48 0.68 +1.75%
Market cap
$6.5B
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
2.12
Beneish M
−3.13
Dividend safety
n/a
Overview Business Profile
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Ionis Pharmaceuticals, Inc. 10-K filed Feb 26, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:25 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 19, 2025: 24 added · 36 removed · 105 modified; 12 with only figures updated; 4 moved without change

  1. Modified · Overview

    In the last year, we delivered on our strategy to create accelerating value for all our stakeholders. With our two independent commercial launch of TRYNGOLZA (olezarsen) in the United Stateslaunches now underway, or U.S., following its approval by the U.S. Food and Drug Administration, or FDA, we began a new chapter as transitioned into a fully integrated commercial-stage biotechnology company. We currently have sixseven marketed medicines to treat serious diseases: TRYNGOLZA (olezarsen), DAWNZERA (donidalorsen), WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen).